All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-08-15T13:34:39.000Z

Comparison of the original and the revised NIH chronic graft-versus-host disease scoring criteria

Aug 15, 2018
Share:

Bookmark this article

Ana Zelic Kerep from the Experimental Transplantation and Immunology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA, and colleagues compared the revised 2014 NIH chronic graft-versus-host disease (cGvHD) severity scoring criteria to the 2005 NIH cGvHD criteria in order to assess the impact of changes to the original NIH cGvHD guideline. The study was published ahead of print on 8 August 2018 in Bone Marrow Transplantation.

Patient characteristics:

  • N = 284 patients with severe and heavily pre-treated cGvHD were prospectively enrolled in the National Cancer Institute's cross-sectional cGvHD natural history study
  • Median age: 46 years (range, 19–71)
  • Disease:
    • Acute leukemias and myelodysplasia: 49%
    • Myeloproliferative diseases: 12%
    • Chronic lymphocytic leukemia: 7%
    • Hodgkin and non-Hodgkin lymphomas: 24%
    • Multiple myeloma: 3%
    • Aplastic anemia, PNH: 3%
    • Other: 2%
  • cGvHD onset
    • Progressive: 34%
    • Quiescent: 32%
    • De novo: 33%
    • Unknown: 1%

Key findings:

  • Frequency of severe global cGvHD based on the 2005 and 2014 NIH criteria: 75% (n = 213) vs 72% (n = 203), P = 0.0009
  • NIH liver involvement score of 0 with no organ involvement was observed in patients based on the 2005 or 2014 NIH criteria: 50% vs 89% respectively, P < 0.0001
  • NIH lung involvement score of 0 with no organ involvement was observed in patients based on the 2005 or 2014 NIH criteria: 23% vs 45%, P < 0.0001
  • 2005 and 2014 NIH global severity scores significantly associated with
    • Reduced grip strength, P < 0.0001
    • Reduced joint range of motion, P = 0.0003
    • The subspecialist evaluation score, P < 0.0001
  • The 2005 and 2014 NIH lung score was significantly associated with a reduced 2-minute walk, Short Form 36 physical component score, human activity profile maximum and activity-adjusted scores, P < 0.0001
  • The 2005 and 2014 NIH joints and fascia score was significantly associated with reduced grip strength, range of motion, and Short Form 36 physical component score, P < 0.0001

In conclusion, this study showed that the revised 2014 NIH cGvHD staging criteria presented milder organ involvement scores for liver and lung involvement, which resulted in overall milder global scores. The authors added that “this score shift could, in some cases, steer the clinician toward less-aggressive therapy.” They further stated that “the 2014 NIH cGvHD scoring criteria in continuing efforts to develop better classification systems more firmly encompassing the biological heterogeneity of this disease.”

  1. Kerep A.Z. et al. Impact of the 2014 NIH chronic graft-versus-host disease scoring criteria modifications assessed in a large cohort of severely affected patients. Bone Marrow Transplant. 2018 Aug 8. DOI: 1038/s41409-018-0224-3. [Epub ahead of print].

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox